Answers are grounded in this paper and cite their sources.
Ibrutinib was superior to chlorambucil in previously untreated patients with CLL or small lymphocytic lymphoma, as assessed by progression-free survival, overall survival, response rate, and improvement in hematologic variables. (Funded by Pharmacyclics and others; RESONATE-2 ClinicalTrials.gov number, NCT01722487.).
No takes yet. Share an insight, caveat, or question.
Burger et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: